LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Consensus statement on viscosupplementation with hyaluronic acid for the management of OA. Y. Henrotin; R. Raman; P. Richette; H. Bard, J. Jerosch; T. Conrozier; X. Chevalier; A. Migliore. Semin Arthritis Rheum. 2015 Read more…
Viscosupplementation with HANOX-M-XL (HAppyCross®) is effective in moderate hip osteoarthritis but is not an alternative to hip joint surgery in patients with severe disease. Results of a “real life” clinical survey in 191 patients. T.Conrozier; M. Bossert; A. Walliser-Lohse; M. Sondag; JC Balblanc. Eur J Musculoskeletal Dis. 2015; 2:49-55. The Read more…
LABRHA actively participated in the 27th Annual Congress of the French Society of Rheumatology which took place in Paris from 7 to 9 December 2014. LABRHA was present with a booth in the exhibition area (F4-F5) where the company’s innovative portfolio and scientific projects were presented to the medical community. Read more…
1st LABRHA EUROPEAN BOARD ON VISCOSUPPLEMENTATION LYON – MAY 22-23, 2014 OBJECTIVE: Organise a meeting and invite experts from several countries of Europe to debate on the viscosupplementation use in both knee and other joints affected by osteoarthritis (OA), share experiences and propose a consensual approach as well as recommendations to Read more…
Mannitol Preserves the Viscoelastic Properties of Hyaluronic Acid in an In Vitro Model of Oxidative Stress by Thierry Conrozier, Pierre Mathieu, Marguerite Rinaudo, Rheumatology and Therapy, December 2014, Volume 1, Issue 1, pp 45-54; doi:10.1007/s40744-014-0001-8. – published online 25 July 2014. Abstract: Introduction Viscosupplementation by intra-articular injection of hyaluronic acid Read more…